|Notice of Intent to Sole Source GSK Arexvy
The Centers for Disease Control and Prevention intends to award one sole source firm fixed price contract modification under contract 75D30123D16727 to GlaxoSmithKline, LLC (GSK) for the addition of the Advisory Committee for Immunization Practices (ACIP) recommended Arexvy vaccine.
The National Center for Immunization and Respiratory Diseases (NCIRD) awarded multiple indefinite delivery, indefinite quantity (IDIQ) one-year contracts for the purchase of standard commercial adult vaccines, manufactured under a current establishment and product license issued by the U.S. Food and Drug Administration (FDA). The vaccines awarded under these contracts will be purchased for NCIRD's immunization awardees (the fifty state health .... Read More
|Solicitation Base Posting Type
|CENTERS FOR DISEASE CONTROL AND PREVENTION